About this trial
To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging （PET/MR）for the diagnosis of primary and metastatic lesions, detection of recurrence or assessment of pathologic response in various types of cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
patients with suspected or new diagnosed or previously treated malignant tumors.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
18F-FAPI-04
Diagnostic test18F-FAPI-04 was injected into the patients before the PET/CT or PET/MR scans
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Diagnostic Performance
Diagnostic accuracy, The sensitivity, specificity and accuracy of 18F-FAPI-04 PET/CT and PET/MR were calculated.
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov